Alchemia new drug application accepted for Fondaparinux
10:41, Monday, 11 May 2009
Sydney - Monday - May 11: (RWE Aust Business News) - Alchemia
(ASX:ACL) partner, Dr Reddy's Laboratories, has received notice of
acceptance of its Abbreviated New Drug Application (ANDA) from the United
States Food and Drug Administration (FDA) for Fondaparinux Sodium.
Dr Reddy's filed the ANDA in March 2009 and this notice of
acceptance indicates that the ANDA will now enter a period of formal
review.
Being the first generic version of fondaparinux, the application
has been marked for priority review under FDA's Generic Initiative for
Value and Efficiency.
First generic products, for which there are no blocking patents
or exclusivity protections on the reference listed drug, are identified
at the time of submission for expedited review.
- Forums
- ASX - By Stock
- TSN
- monkey buy at 11c
monkey buy at 11c, page-239
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, MD & CEO
Charles Armstrong
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online